Protalix management should've spoken to Merck not Pfizer about a takeover. $2 billion is nothing if it gives Merck a way around their competitions method based (Chinese Hamster Ovary cells) manufacturing patents.
Announcing a new strategic direction for the company in which they offer the technology for modest upfront fee for a NON-exclusive license plus 5% future royalty on future sales will have all the generic manufacturers knocking on their door. Signing their first deal with South Korea's Hanwha Chemical will cause their stock price to explode. Hanwha is the South Korean biosimilars manufacture that Merck teamed up with to bring its biosimilar version of Amgen's Enbre to market, until the USPTO extended Amgen's patent for another 16 years. Partner with Hanwha and they will get Merck's attention. Merck is ready to stab all these big pharma's in the back and steal their highly profitable drugs sales.
Sign Teva, Hospira and Celltrion right after Hanwha and Protalix's market cap will instantly grow beyond the takeover aspirations of Pfizer.
Looking at a the 2 year chart you could have bought and sold PLX over and over again. PLX was in the member's section on ChannelingStocksdotcom website. They show you how to buy and sell the same stock over and over again
This Low Float Rocket will hit $6++ before FDA decision on October 17 ...PSDV will move into double digits easily with FDA approval for Blockbuster Candidate Iluven .There is NO FDA approved drugs for DME (Diabetic Macular Edema) .
Upon US approval of Iluvien, pSivida would be entitled to receive a $25 million milestone payment from Alimera and 20 percent of net profits, as defined, on sales of the drug by Alimera.
DME is a potentially blinding disease that affects over one million people in the United States. Currently there are no FDA approved drugs for the treatment of DME.The U.S. market for DME is $1.5 billion to $4 billion.
Pfizer is third largest Shareholder of PSDV holding 1.9 M Shares . PSDV is very close to profitability .
Market Cap: $90 M
Cash: $21 M
Shares Out: 26.8 M ( 10.4 M shares held by Insiders & Institutions)
“We are very pleased that the FDA has accepted Alimera Sciences’ recently resubmitted New Drug Application for ILUVIEN® for chronic Diabetic Macular Edema (DME) and has set a PDUFA target date of October 17, 2013." Upon US approval of Iluvien, pSivida would be entitled to receive a $25 million milestone payment from Alimera and 20 percent of net profits, as defined, on sales of the drug by Alimera.
The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic DME considered insufficiently responsive to available therapies, licensed to Alimera Sciences, Inc., has received marketing authorization in Austria, France, Germany, Portugal, Spain and the U.K. and is awaiting authorization in Italy.
Their failure has nothing to do with being Jews. Jews make tons of money for themselves and their shareholders. They fail because they are Foreigners who don't know how to play the American stock market game to maximize value. Instead they use shareholders as an ATMs to withdraw cash any time they want. Their arrogance and hateful attitude towards shareholders will only leave them more cashless and desperate in the future. Everytime you dilute your shareholders it gets harder and harder to raise cash and you have to sell for cheaper and cheaper until you shares are worthless and you're begging for a buyout to avoid bankruptcy. Men like Frost are as much Financiers as Scientists. PLX management are typical doctors with God Simplex who think people should be kneeling to them.
We are in the middle of a biotech stock market bubble and still NO ONE has even heard of Protalix.
Their first big failure was listing on the NYSE.
That's where small caps go to die.
If they want to maximize shareholder value they need to move their listing to the Nasdaq and pay analysts for coverage.
With more interest in the stock, the price would be higher and management wouldn't have to sell shareholders short everytime they need to raise capital.
Look at CLDX. It was at $5 for the longest time. Now without accomplishing anything new, their company is worth $33 per share with a market cap of $3 billion. They'd only have to sell 2 million shares to raise the same amount of capital that PLX sold 12 million shares for.
Their CFO is the most incompetent imbecile in the world.
vensh_u_to----- Tell me do you plan to attend PLX annual meeting? I will be in front row to harrass the PLX top management for being greedy utter failures on protecting and growing shareholder value.
I've watched this sleazy company for past 4 years. Don't trust this management team whatsoever. We just saw them do a totally dilutive financing that slammed anyone who has bought in the past year. They just released their Def14A. This management team gives themselves stock awards everytime price drops. We should now see this recover. Their methods are clear. I am now back in and will ride it to the next press release announcing something to drive PPS up.
FDA approval for Focalin XR expected for this Quarter...GL
This Low float Stock awaiting 8 FDA approvals and has another 2 Potential Blockbusters ready for Phase 3
Foclian XR alone which is Partnered with Par Pharma will drive IPCI deep into Profitability quickly after Market Launch .There is NO generic version of Focalin XR available on the Market , IPCI & Par will be the first here and its normal that the first generic takes 30%-40% of market share quickly after launch .
5-6 FDA approvals expcted within 12 months .This Gem has everything to move into Double Digits the Market Cap of $40 Million is a Big Joke .
Market Cap:$ 42 M
Cash : $3 M
Shares Out: 21 Mil..(10 Mil Shares held by Insiders/Institutions)
Low Float: 11 M
8 Generic Drug Applications Filed with the FDA
We currently have eight Abbreviated New Drug Applications awaiting FDA approval. These include generics of Focalin XR® Effexor XR®, Protonix ®' Glucophage ® XR,Seroquel XR®, Lamictaf® XR Keppra XR® and Pristiq® .Together, these products represent approximately $4.78 of branded and generic sales.
Our lead product, a generic version of Focal in XR®, is partnered with Par Pharmaceuticals Inc., a top ten U.S.pharmaceutical company.As a result of a settlement with the innovator company, we expect to marketing of our generic versions ofFocalin XR® upon approval. We have a ten year profit-sharing agreement with Par for the sale of a generic version of Focal in XR® in the U.S.,which commences with the commercial launch of the product by Par .